15. Loss of MSH2 and MSH6 is frequently observed in prostate neoplasms with mismatch repair deficiency

Deficiency in DNA mismatch repair function in neoplasms can be assessed through immunohistochemical (IHC) analysis of MLH1, MSH2, MSH6, and PMS2 proteins to detect loss of expression of the mismatch repair (dMMR) proteins. dMMR is an FDA-approved, histology-agnostic biomarker for the use of pembrolizumab during specific anti-programmed cell death 1 (PD-1)-based immune checkpoint inhibitor (ICI) therapy regimens.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research